- Synthesis, docking study and inhibitory activity of 2,6-diketopiperazines derived from α-amino acids on HDAC8
-
Diketopiperazines (DKPs) have been regarded as an important scaffold from the viewpoint of synthesis due to their biological properties for the treatment of several diseases, including cancer. In this work, two novel series of enantiomeric 2,6-DKPs derived from α-amino acids were synthesized through nucleophilic substitution and intramolecular cyclization reactions. All the compounds were docked against histone deacetylase 8 (HDAC8), which is a promising target for the development of anticancer drugs. These compounds bound into the active site of HDAC8 in a similar way to Trichostatin A (TSA), which is an HDAC8 inhibitor. This study showed that the conformation of the 2,6-DKP ring, stereochemistry, and the type of substituent on the chiral center had an important role in the binding modes. The Gibbs free energies and dissociation constants values of HDAC8-ligand complexes showed that compounds (S)-4hBn, (S)-4m, (R)-4h, and (R)-4m were more stable and affine towards HDAC8 than TSA. The inhibitory activities of 4a, (S)-4h, (S)- and (R)-4(g, l, m) were evaluated in vitro on HDAC8. It was found that compounds (R)-4g (IC50 = 21.54 nM) and (R)-4m (IC50 = 10.81 nM) exhibited better inhibitory activities than TSA (IC50 = 28.32 nM). These results suggested that 2,6-DKPs derivatives may be promising anticancer agents for further biological studies.
- Garrido González, Flor Paulina,Mancilla Percino, Teresa
-
supporting information
(2020/07/21)
-
- CYCLIC PEPTIDES AS C5 A RECEPTOR ANTAGONISTS
-
The invention relates to cyclic peptide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to cyclic peptide C5a receptor antagonists of formula (Ia)or formula (Ib), or pharmaceutically acceptable salts thereof,wherein R1a, R1b, R2, R3 and R4 areas defined in the description. C5a receptor antagonists are potentially useful in the treatment of a wide range of 1 disorders,including inflammatory disorders and immune disorders.
- -
-
Page/Page column 66
(2018/02/28)
-
- Synthesis and Biological Evaluation of Modified Miuraenamides
-
Miuraenamides, secondary metabolites of the marine myxobacterium Paraliomyxa miuraensis do not only show a high structural similarity to other cyclodepsipeptides isolated from sponges or terrestrial myxobacteria but they also exhibit a similar mode of act
- Kappler, Sarah,Karmann, Lisa,Prudel, Cynthia,Herrmann, Jennifer,Caddeu, Giulia,Müller, Rolf,Vollmar, Angelika M.,Zahler, Stefan,Kazmaier, Uli
-
p. 6952 - 6965
(2018/11/25)
-
- TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS
-
Bicyclic dihydropyrimidine-carboxamide compounds of formula I described herein inhibit Rho Kinase and may be used for the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
- -
-
Paragraph 0443-0444; 0461
(2018/08/20)
-
- Method for preparing alanine derivative
-
The invention discloses a method for preparing an alanine derivative represented by a formula (I) shown in the description. The alanine derivative can serve as synthesis intermediates of opium receptor regulators, such as a synthesis intermediate of eluxadoline. According to the method, chiral tyrosine which is cheap and readily available serves as an initial raw material, a bran-new synthesis route for preparing the alanine derivative is provided, the total yield of the entire reaction route is high, the cost is low, the reaction conditions are mild, and the operation is simple and safe, so that the method is applicable to large-scale industrial production.
- -
-
Paragraph 0114; 0115; 0116
(2016/10/10)
-
- NOVEL PRODRUGS AND COMBINATIONS FOR TREATMENT OF HYPERTENSION AND CARDIOVASCULAR DISEASES
-
The invention relates a pharmaceutical composition comprising (i) prodrugs of NEP inhibitors, (ii) mutual prodrugs of angiotensin receptor antagonist and a NEP inhibitor, (iii) a combination of an angiotensin receptor antagonist prodrug and a NEP inhibitor and (iv) a combination of angiotensin receptor antagonist including prodrug, a NEP inhibitor prodrug and a diuretic drug (v) a combination of angiotensin receptor antagonist, a NEP inhibitor prodrug and a calcium channel blocker. The angiotensin receptor antagonist is selected from the group selected from the group consisting of allisartan, elisartan, candesartan, eprosartan, irbesartan, losartan, saprisartan, tasosartan, telmisartan and valsartan. The invention also includes a method for treating hypertension, heart failure such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction (such as Alzheimer's), glaucoma and stroke.
- -
-
-
- MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO
-
The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as a single agent or in combination with one or more additional pharmacetical agents, such as, an inhibitor of DPP-IV, a biguanide, an SGLT2 inhibitor, or an alpha-glucosidase inhibitor, in the treatment of, for example, a disorder selected from: a GPR119-receptor-related disorder; a condition ameliorated by increasing a blood incretin level; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.
- -
-
Page/Page column 191
(2011/10/31)
-
- Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: Synthesis, stability, antiviral activity, and in vivo transport studies
-
Eight novel single amino acid (6-11) and dipeptide (12, 13) tyrosine P-O esters of cyclic cidofovir ((S)-cHPMPC, 4) and its cyclic adenine analogue ((S)-cHPMPA, 3) were synthesized and evaluated as prodrugs. In vitro IC 50 values for the prodrugs (50 0.3-35 μM); there was no cytoxicity with KB or HFF cells at ≤100 μM. The prodrugs exhibited a wide range of half-lives in rat intestinal homogenate at pH 6.5 (30-1732 min) with differences of 3-10× between phostonate diastereomers. The tyrosine alkylamide derivatives of 3 and 4 were the most stable. (l)-Tyr-NH-i-Bu cHPMPA (11) was converted in rat or mouse plasma solely to two active metabolites and had significantly enhanced oral bioavailability vs parent drug 1 in a mouse model (39% vs 5%).
- Zakharova, Valeria M.,Serpi, Michaela,Krylov, Ivan S.,Peterson, Larryn W.,Breitenbach, Julie M.,Borysko, Katherine Z.,Drach, John C.,Collins, Mindy,Hilfinger, John M.,Kashemirov, Boris A.,McKenna, Charles E.
-
experimental part
p. 5680 - 5693
(2011/10/18)
-
- Synthesis and structure revision of tyroscherin, and bioactivities of its stereoisomers against IGF-1-dependent tumor cells
-
Synthesis of the proposed structure of tyroscherin, a growth inhibitor of IGF-1-dependent cancer cells, was succeeded by one-pot Julia coupling. However, spectral data of the synthetic compound were not identical with those of natural tyroscherin. The stereochemistry of tyroscherin is revised to be 2S,3R,8R,10R by syntheses of stereoisomers. Synthetic tyroscherin showed more potent activity than its stereoisomers against IGF-1-dependent cancer cells.
- Ishigami, Ken,Katsuta, Ryo,Shibata, Chié,Hayakawa, Yoichi,Watanabe, Hidenori,Kitahara, Takeshi
-
experimental part
p. 3629 - 3638
(2009/09/25)
-
- Ligand creation via linking - A rapid and convenient method for construction of novel supported PyOX-ligands
-
A novel supported amino alcohol linker was synthesized and utilized for attachment of picolinic acid derivatives onto different supports. When the resin bound molecule was further activated, the PyOX-moiety could be constructed reliably in enantiopure form. Furthermore, an efficient Pd-catalyzed modification of a picolinic acid derivative is presented.
- Oila, Markku J.,Tois, Jan E.,Koskinen, Ari M.P.
-
p. 10748 - 10756
(2007/10/03)
-
- An aldol-based approach to the synthesis of the antibiotic anisomycin
-
Chemical equation presented A new approach to the synthesis of the antibiotic anisomycin is reported that relies upon a key aldol disconnection. The glycolate aldol coupling proceeds in 75% yield and with >95% diastereoselectivity, which allows the 13-step synthesis to proceed in 35% overall yield.
- Hulme, Alison N.,Rosser, Edward M.
-
p. 265 - 267
(2007/10/03)
-
- A synthetic route to the tripeptide unit of geodiamolicle-B
-
A better route to the tripeptide unit of geodiamolide-B is investigated using the corresponding amino acids L-alanine and N-methyl-D-tyrosine.
- Beiagali,Kocienski
-
p. 562 - 565
(2007/10/03)
-
- Polypeptide compound and a process for preparation thereof
-
A polypeptide compound having antimicrobial activity of the following general formula: STR1 wherein R1 is hydrogen or acyl group, R2 is hydroxy or acyloxy, R3 is hydroxysulfonyloxy, and R4 is hydrogen or carbamoyl, with proviso that R1 is not palmitoyl, when R2 is hydroxy, R3 is hydroxysulfonyloxy and R4 is carbamoyl, and a pharmaceutically acceptable salt thereof.
- -
-
-
- Studies on cyclodepsipeptides - Part II : The total synthesis of jaspamide and geodiamolide-D
-
The total synthesis of cyclodepsipeptides jaspamide and geodiamolide D have been presented.
- Rama Rao,Gurjar, Mukund K.,Nallaganchu, Bhaskara Rao,Bhandari, Ashok
-
p. 7085 - 7088
(2007/10/02)
-